Physician profile
Jay J Lin
NPI 1275551251
$16,034.91
in general payments reported to CMS, 2019-2025
33 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,514 · 2020: $2,455 · 2021: $2,637 · 2022: $1,392 · 2023: $1,350 · 2024: $578 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.55 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,931.00 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $1,288.72 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,190.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,134.21 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $1,044.06 | 2019-2023 | |
| Lilly USA, LLC | $990.36 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $981.31 | 2019-2025 | Jardiance, Synjardy |
| Allergan, INC. | $953.47 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $926.19 | 2019-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $764.18 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $722.91 | 2019-2025 | |
| Novo Nordisk INC | $502.19 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $278.11 | 2019-2021 | |
| Viatris Specialty LLC | $228.38 | 2025 | Yupelri |
| Exact Sciences Corporation | $200.41 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $198.47 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.67 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $181.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $146.67 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $146.24 | 2023 | Quviviq |
| Mylan Specialty L.P. | $139.72 | 2024 | Yupelri |
| Medtronic Vascular, INC. | $137.99 | 2019 | |
| Aurinia Pharma U.S., INC. | $125.00 | 2023 | Lupkynis |
| Mallinckrodt Enterprises LLC | $124.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $122.00 | 2019 | |
| Horizon Therapeutics Plc | $97.99 | 2020-2021 | |
| Eisai INC. | $96.00 | 2020-2022 | |
| Stryker Corporation | $72.53 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $31.50 | 2023 | Livalo, Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.08 | 2025 | Caplyta |
| Seqirus USA INC | $24.07 | 2025 | Flucelvax, Fluad |
| Sumitomo Pharma America, INC. | $19.95 | 2025 | Gemtesa |
| Abbott Laboratories | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.